Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3, Randomized, Double-blind, Comparator- and Placebo-controlled Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TLC590 for Postsurgical Pain Management Following Inguinal Hernia Repair

NCT05161637 is registered in ClinicalTrials.gov with Taiwan Liposome Company as lead sponsor.

NCT NCT05161637
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05161637 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3, Randomized, Double-blind, Comparator- and Placebo-controlled Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TLC590 for Postsurgical Pain Management Following Inguinal Hernia Repair
Lead sponsor
Taiwan Liposome Company
Phase
Phase 2/3
Overall status
Unknown status
Start date
April 30, 2025
Completion date
December 31, 2025
Enrollment
415 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

postsurgical pain management